Grizard D, Barthomeuf C
Laboratoire de pharmacognosie et de biotechnologies, UFR de pharmacie, Clermont-Ferrand, France.
Reprod Nutr Dev. 1999 Sep-Dec;39(5-6):563-88. doi: 10.1051/rnd:19990505.
Prebiotic agents are food ingredients that are potentially beneficial to the health of consumers. The main commercial prebiotic agents consist of oligosaccharides and dietary fibres (mainly inulin). They are essentially obtained by one of three processes: 1) the direct extraction of natural polysaccharides from plants; 2) the controlled hydrolysis of such natural polysaccharides; 3) enzymatic synthesis, using hydrolases and/or glycosyl transferases. Both of these enzyme types catalyse transglycosylation reactions, allowing synthesis of small molecular weight synthetic oligosaccharides from mono- and disaccharides. Presently, in Europe, inulin-type fructans, characterised by the presence of fructosyl units bound to the beta-2,1 position of sucrose, are considered as one of the carbohydrate prebiotic references. Prebiotics escape enzymatic digestion in the upper gastrointestinal tract and enter the caecum without change to their structure. None are excreted in the stools, indicating that they are fermented by colonic flora so as to give a mixture of short-chain fatty acids (acetate, propionate and butyrate), L-lactate, carbon dioxide and hydrogen. By stimulating bifidobacteria, they may have the following implications for health: 1) potential protective effects against colorectal cancer and infectious bowel diseases by inhibiting putrefactive bacteria (Clostridium perfringens ) and pathogen bacteria (Escherichia coli, Salmonella, Listeria and Shigella ), respectively; 2) improvement of glucid and lipid metabolisms; 3) fibre-like properties by decreasing the renal nitrogen excretion; 4) improvement in the bioavailability of essential minerals; and 5) low cariogenic factor. These potential beneficial effects have been largely studied in animals but have not really been proven in humans. The development of a second generation of oligosaccharides and the putative implication of a complex bacterial trophic chain in the intestinal prebiotic fermentation process are also discussed.
益生元制剂是对消费者健康有潜在益处的食品成分。主要的商业益生元制剂包括低聚糖和膳食纤维(主要是菊粉)。它们基本上通过以下三种方法之一获得:1)从植物中直接提取天然多糖;2)对这类天然多糖进行可控水解;3)利用水解酶和/或糖基转移酶进行酶促合成。这两种酶都催化转糖基化反应,能从单糖和二糖合成小分子量的合成低聚糖。目前在欧洲,以与蔗糖的β-2,1位相连的果糖基单元为特征的菊粉型果聚糖被视为碳水化合物益生元参考物之一。益生元在上消化道中不会被酶消化,其结构不变地进入盲肠。没有益生元会随粪便排出,这表明它们会被结肠菌群发酵,从而产生短链脂肪酸(乙酸、丙酸和丁酸)、L-乳酸、二氧化碳和氢气的混合物。通过刺激双歧杆菌,它们可能对健康有以下影响:1)分别通过抑制腐败菌(产气荚膜梭菌)和病原菌(大肠杆菌、沙门氏菌、李斯特菌和志贺氏菌),对结直肠癌和感染性肠道疾病具有潜在保护作用;2)改善糖类和脂质代谢;3)通过减少肾脏氮排泄表现出类似纤维的特性;4)提高必需矿物质的生物利用度;5)低致龋因素。这些潜在的有益作用在动物身上已得到大量研究,但在人类身上尚未得到切实证明。本文还讨论了第二代低聚糖的发展以及复杂细菌营养链在肠道益生元发酵过程中的假定作用。